EVALUATING THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF DELAMANID IN COMBINATION WITH OPTIMIZED MULTIDRUG BACKGROUND REGIMEN (OBR) FOR MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB) IN HIV-INFECTED AND HIV-UNINFECTED CHILDREN WITH MDR-TB: